

Title (en)

PHARMACEUTICAL FORMULATION CONTAINING AN LTB4 ANTAGONIST, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF

Title (de)

ARZNEIMITTELFORMULIERUNG, ENTHALTEND EINEN LTB4-ANTAGONISTEN, SOWIE VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG

Title (fr)

FORMULATION DE MEDICAMENT CONTENANT UN ANTAGONISTE DE LTB SB 4 /SB , ET PROCEDES DE PRODUCTION ET UTILISATION DE CETTE FORMULATION DE MEDICAMENT

Publication

**EP 1682086 A2 20060726 (DE)**

Application

**EP 04790806 A 20041023**

Priority

- EP 2004012015 W 20041023
- DE 10350528 A 20031029

Abstract (en)

[origin: WO2005041855A2] The invention relates to a novel pharmaceutical formulation containing an LTB4 antagonist of formula (I), wherein A, R1, R2, R3, and R4 have the meaning indicated in claim 1, the pharmaceutically acceptable acid addition salt thereof, glycoside, O-sulfate, or glucuronide as an active substance, and at least one optional pharmaceutically acceptable auxiliary agent and/or carrier, the active substance being provided as a solid solution or solid dispersion in a polymer matrix. The invention also relates to the production thereof, the use thereof as a medicament, and said solid solutions and dispersions.

IPC 8 full level

**A61K 9/00** (2006.01); **A61K 9/10** (2006.01); **A61K 9/14** (2006.01); **A61K 9/16** (2006.01); **A61K 31/155** (2006.01)

CPC (source: EP KR US)

**A61K 9/10** (2013.01 - KR); **A61K 9/1617** (2013.01 - EP US); **A61K 9/1635** (2013.01 - EP US); **A61K 31/155** (2013.01 - EP KR US);  
**A61P 1/04** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 7/08** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP);  
**A61P 11/06** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/28** (2017.12 - EP)

Citation (search report)

See references of WO 2005041855A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

**WO 2005041855 A2 20050512; WO 2005041855 A3 20070510;** AU 2004285271 A1 20050512; BR PI0416121 A 20070102;  
CA 2544049 A1 20050512; CN 101123950 A 20080213; DE 10350528 A1 20050609; EP 1682086 A2 20060726; IL 175293 A0 20060905;  
JP 2007513068 A 20070524; KR 20060108696 A 20061018; MX PA06004435 A 20060620; RU 2006118273 A 20071220;  
US 2005129768 A1 20050616; ZA 200601360 B 20070328

DOCDB simple family (application)

**EP 2004012015 W 20041023;** AU 2004285271 A 20041023; BR PI0416121 A 20041023; CA 2544049 A 20041023;  
CN 200480032290 A 20041023; DE 10350528 A 20031029; EP 04790806 A 20041023; IL 17529306 A 20060427; JP 2006537151 A 20041023;  
KR 20067010481 A 20060529; MX PA06004435 A 20041023; RU 2006118273 A 20041023; US 97703504 A 20041029;  
ZA 200601360 A 20060215